A carefully monitored prescription pathway for eligible adults living with HIV-associated lipodystrophy, guided by thoughtful evaluation, discreet care and continued provider support.
Tesamorelin is a growth-hormone-releasing factor analogue used to reduce excess abdominal fat in adults living with HIV-associated lipodystrophy. It is a specialized medical service rather than a general weight-management or cosmetic body-contouring option.
Your provider reviews your diagnosis, existing HIV care, current medications, health history and whether Tesamorelin aligns with your clinical needs.
Relevant medical information and laboratory markers are reviewed before a treatment plan is considered. Additional coordination with your existing care team may be needed.
When prescribed, Tesamorelin is administered through a subcutaneous injection. Your provider explains preparation, administration and appropriate injection-site rotation.
Follow-up appointments allow your provider to review response, relevant laboratory findings, possible reactions and continued treatment suitability.
Tesamorelin is intended for a specific medical condition involving excess abdominal fat in adults living with HIV-associated lipodystrophy.
No. It is not designed as a general weight-management or cosmetic body-contouring treatment.
It is typically given as a subcutaneous injection according to the prescribed treatment plan. Your provider will explain the exact method.
Monitoring may include laboratory testing, treatment-response reviews and evaluation of possible side effects. Your schedule will be personalized.
